{"id":478190,"date":"2020-04-07T11:28:01","date_gmt":"2020-04-07T11:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=478190"},"modified":"2020-04-07T11:28:01","modified_gmt":"2020-04-07T11:28:01","slug":"merkel-cell-carcinoma-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/merkel-cell-carcinoma-market-insights-epidemiology-and-market-forecast2030_478190.html","title":{"rendered":"Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2030"},"content":{"rendered":"
\"Merkel<\/a><\/div>\n

DelveInsight has launched a new report on Merkel Cell Carcinoma Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Merkel Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Merkel Cell Carcinoma , historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Merkel Cell Carcinoma market report provides current treatment practices, emerging drugs, Merkel Cell Carcinoma market share of the individual therapies, current and forecasted Merkel Cell Carcinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Merkel Cell Carcinoma treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Merkel Cell Carcinoma (MCC) is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma.<\/div>\n
 <\/div>\n
\"\"<\/div>\n
 <\/div>\n
Request for :- <\/strong>free sample page<\/a><\/div>\n
 <\/div>\n
Epidemiology<\/strong><\/em><\/div>\n
The Merkel Cell Carcinoma epidemiology division provide insights about historical and current Merkel Cell Carcinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/em><\/div>\n
 <\/div>\n
Report key facts:- <\/em><\/strong><\/div>\n
 <\/div>\n
1. <\/em><\/strong><\/strong>As per “Skin Cancer Foundation”, Merkel cell carcinoma (MCC) is 40 times more rare than melanoma, with an estimated one case per 130,000 people in the US.<\/div>\n
 <\/div>\n
 <\/div>\n
2. <\/strong><\/strong>According to a study in Germany, the incidence rate of MCC is 0.30 (women) and 0.40 (men) (1988–2010) and in Eastern France the incidence rate is 0.13 (1980–2004) (Dirk Schadendorf et al.)<\/div>\n
\n

3.  As per study conducted by João Pedreira Duprat, et al. (2011), The estimated annual incidence of MCC is 0.23 per 100,000 individuals for Caucasians, whereas the incidence in those of African descent is 0.01 per 100,000 and appears to be even lower in Polynesians.<\/p>\n<\/div>\n

In most people, the first sign of Merkel cell carcinoma is a small bump (nodule) on the skin. This bump is usually firm and appears either skin-colored or red-purple. It also tends to grow rapidly. Often, there no symptoms associated with the nodule<\/em><\/strong><\/div>\n
 <\/div>\n
Key major companies are working on MCC that are given below:- <\/em><\/strong><\/div>\n
 <\/div>\n
\n

1. Merck Pharma Co.
2. Incvte Corporation
3. Kartos Therapeutics<\/p>\n<\/div>\n

Name of covered drugs that are given below:-<\/strong><\/div>\n
 <\/strong><\/div>\n
\n

1. Avelumab
2. Pembrolizumab
3. INCMGA00012<\/p>\n

Table of contents<\/a><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Merkel Cell Carcinoma<\/p>\n

3. Competitive Intelligence Analysis for Merkel Cell Carcinoma<\/p>\n

4. Merkel Cell Carcinoma : Market Overview at a Glance<\/p>\n

4.1. Merkel Cell Carcinoma Total Market Share (%) Distribution in 2017<\/p>\n

4.2. Merkel Cell Carcinoma Total Market Share (%) Distribution in 2030<\/p>\n

5. Merkel Cell Carcinoma : Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.2. Sign and Symptoms <\/p>\n

5.3. Pathophysiology <\/p>\n

5.4. Risk Factors <\/p>\n

5.5. Diagnosis <\/p>\n

6. Patient Journey<\/p>\n

7. Merkel Cell Carcinoma Epidemiology and Patient Population<\/p>\n

7.1. Epidemiology Key Findings<\/p>\n

7.2. Assumptions and Rationale: 7MM<\/p>\n

7.3. Epidemiology Scenario: 7MM<\/p>\n

7.3.1. Merkel Cell Carcinoma Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n

7.4. United States Epidemiology<\/p>\n

7.4.1. Merkel Cell Carcinoma Epidemiology Scenario in the United States (2017-2030)<\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/p>\n

7.5.1. Germany Epidemiology<\/p>\n

7.5.1.1. Merkel Cell Carcinoma Epidemiology Scenario in Germany (2017-2030)<\/p>\n

7.5.2. France Epidemiology<\/p>\n

7.5.2.1. Merkel Cell Carcinoma Epidemiology Scenario in France (2017-2030)<\/p>\n

7.5.3. Italy Epidemiology<\/p>\n

7.5.3.1. Merkel Cell Carcinoma Epidemiology Scenario in Italy (2017-2030)<\/p>\n

7.5.4. Spain Epidemiology<\/p>\n

7.5.4.1. Merkel Cell Carcinoma Epidemiology Scenario in Spain (2017-2030)<\/p>\n

7.5.5. United Kingdom Epidemiology<\/p>\n

7.5.5.1. Merkel Cell Carcinoma Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n

7.5.6. Japan Epidemiology<\/p>\n

7.5.6.1. Merkel Cell Carcinoma Epidemiology Scenario in Japan (2017-2030)<\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Merkel Cell Carcinoma Treatment and Management<\/p>\n

8.2. Merkel Cell Carcinoma Treatment Algorithm <\/p>\n

9. Unmet Needs<\/p>\n

10. Key Endpoints of Merkel Cell Carcinoma Treatment<\/p>\n

11. Marketed Products<\/p>\n

11.1. List of Marketed Products in the 7MM<\/p>\n

11.2. Drug Name: Company Name<\/p>\n

11.2.1. Product Description<\/p>\n

11.2.2. Regulatory Milestones<\/p>\n

11.2.3. Other Developmental Activities<\/p>\n

11.2.4. Pivotal Clinical Trials<\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/p>\n

List to be continued in report<\/p>\n

12. Emerging Therapies<\/p>\n

12.1. Key Cross<\/p>\n

12.2. Drug Name: Company Name<\/p>\n

12.2.1. Product Description<\/p>\n

12.2.2. Other Developmental Activities<\/p>\n

12.2.3. Clinical Development<\/p>\n

12.2.4. Safety and Efficacy<\/p>\n

12.2.5. Product Profile<\/p>\n

List to be continued in report<\/p>\n

13. Merkel Cell Carcinoma : Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/p>\n

13.2. Merkel Cell Carcinoma Market Size in 7MM<\/p>\n

13.3. Merkel Cell Carcinoma Market Size by Therapies in the 7MM<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

15.1. United States: Market Size<\/p>\n

15.1.1. Merkel Cell Carcinoma Total Market Size in the United States<\/p>\n

15.1.2. Merkel Cell Carcinoma Market Size by Therapies in the United States<\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/p>\n

15.3. Germany Market Size<\/p>\n

15.3.1. Merkel Cell Carcinoma Total Market Size in Germany<\/p>\n

15.3.2. Merkel Cell Carcinoma Market Size by Therapies in Germany<\/p>\n

15.4. France Market Size<\/p>\n

15.4.1. Merkel Cell Carcinoma Total Market Size in France<\/p>\n

15.4.2. Merkel Cell Carcinoma Market Size by Therapies in France<\/p>\n

15.5. Italy Market Size<\/p>\n

15.5.1. Merkel Cell Carcinoma Total Market Size in Italy<\/p>\n

15.5.2. Merkel Cell Carcinoma Market Size by Therapies in Italy<\/p>\n

15.6. Spain Market Size<\/p>\n

15.6.1. Merkel Cell Carcinoma Total Market Size in Spain<\/p>\n

15.6.2. Merkel Cell Carcinoma Market Size by Therapies in Spain<\/p>\n

15.7. United Kingdom Market Size<\/p>\n

15.7.1. Merkel Cell Carcinoma Total Market Size in the United Kingdom<\/p>\n

15.7.2. Merkel Cell Carcinoma Market Size by Therapies in the United Kingdom<\/p>\n

15.8. Japan Market Outlook<\/p>\n

15.8.1. Japan Market Size<\/p>\n

15.8.2. Merkel Cell Carcinoma Total Market Size in Japan<\/p>\n

15.8.3. Merkel Cell Carcinoma Market Size by Therapies in Japan<\/p>\n

16. Access and Reimbursement Overview of Merkel Cell Carcinoma<\/p>\n

17. KOL Views<\/p>\n

18. Market Drivers<\/p>\n

19. Market Barriers<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About<\/strong><\/em> DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/em><\/p>\n